Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 1, 2003

View Archived Issues

Concerta approved for ADHD in Canada

Grant supports development of cancer vaccines at Epimmune using analogue epitopes

Sustained symptom relief induced by tamsulosin in BPH

Snapshots on the treatment of Flavivirus infection

Progress continues at BioCryst in Q2

Quarterly developments discussed by PDL

Resten-NG continues progress in cardiovascular antisense program

Cubist awarded two SBIR grants

Structural GenomiX completes crystal structure of SARS coronavirus protease

New phase II trial studies of Genasense in combination with rituximab/fludarabine for CLL

Aventis and ImmunoGen combine forces to develop anticancer therapeutics

Antiemetic properties reported for known analgesic agent

Novel, more stable compositions of statin claimed

Selective A2B antagonists identified by OSI researchers

Schering-Plough patents new series of antiinflammatory compounds

Tachykinin antagonists with antiemetic activity described in recent patent

Inhibitors of beta-amyloid reported in the patent literature by BMS

Ropinirole slows progression of PD compared to levodopa therapy

Spirodiketopiperazine CCR5 antagonist enters the clinic as a potential new anti-HIV agent

Neovascular targeting therapy developed at Munich Biotech

Pleconaril safe and effective in the treatment of infections caused by picornaviruses

Evidence of visual memory improvement found with donepezil after TBI

Effective use of divalproex sodium described for cluster B personality disorder

Good activity profile established for dalbavancin against Gram-positive bacteria

Early detection of lymph node metastases in prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...